Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial.

[1]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[2]  T. Callister,et al.  Progression of Coronary Artery Calcium and Risk of First Myocardial Infarction in Patients Receiving Cholesterol-Lowering Therapy , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[3]  H. Hecht,et al.  Relation of aggressiveness of lipid-lowering treatment to changes in calcified plaque burden by electron beam tomography. , 2003, The American journal of cardiology.

[4]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[5]  Robert Detrano,et al.  Combined Use of Computed Tomography Coronary Calcium Scores and C-Reactive Protein Levels in Predicting Cardiovascular Events in Nondiabetic Individuals , 2002, Circulation.

[6]  A. Hofman,et al.  Coronary calcification detected by electron-beam computed tomography and myocardial infarction. The Rotterdam Coronary Calcification Study. , 2002, European heart journal.

[7]  S. Achenbach,et al.  Influence of Lipid-Lowering Therapy on the Progression of Coronary Artery Calcification: A Prospective Evaluation , 2002, Circulation.

[8]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[9]  Tw.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002, The Lancet.

[10]  V. Athyros,et al.  Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention , 2002, Current medical research and opinion.

[11]  Y. Arad,et al.  Rationale and design of the St. Francis Heart Study: a randomized clinical trial of atorvastatin plus antioxidants in asymptomatic persons with elevated coronary calcification. , 2001, Controlled clinical trials.

[12]  H. C. Stary,et al.  The development of calcium deposits in atherosclerotic lesions and their persistence after lipid regression. , 2001, The American journal of cardiology.

[13]  Paul M. Ridker,et al.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.

[14]  D. Steinberg,et al.  The oxidative modification hypothesis of atherosclerosis: does it hold for humans? , 2001, Trends in cardiovascular medicine.

[15]  Y. Arad,et al.  Prediction of coronary events with electron beam computed tomography. , 2000, Journal of the American College of Cardiology.

[16]  J. Gardin,et al.  Coronary artery calcium evaluation by electron beam computed tomography and its relation to new cardiovascular events. , 2000, The American journal of cardiology.

[17]  M. Budoff,et al.  Rates of progression of coronary calcium by electron beam tomography. , 2000, The American journal of cardiology.

[18]  T. Callister,et al.  Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. , 2000, Circulation.

[19]  S. Yusuf,et al.  Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[20]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[21]  Y. Arad,et al.  Predictive value of electron beam computed tomography of the coronary arteries. 19-month follow-up of 1173 asymptomatic subjects. , 1996, Circulation.

[22]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[23]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[24]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[25]  J. Strong,et al.  Long-term induction and regression of diet-induced atherosclerotic lesions in rhesus monkeys. I. Morphological and chemical evidence for regression of lesions in the aorta and carotid and peripheral arteries. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[26]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[27]  H. Stähelin,et al.  Increased risk of cardiovascular disease at suboptimal plasma concentrations of essential antioxidants: an epidemiological update with special attention to carotene and vitamin C. , 1993, The American journal of clinical nutrition.

[28]  R. Detrano,et al.  Quantification of coronary artery calcium using ultrafast computed tomography. , 1990, Journal of the American College of Cardiology.

[29]  M. Bond,et al.  A study of atherosclerosis regression in Macaca mulatta. IV. Changes in coronary arteries from animals with atherosclerosis induced for 19 months and then regressed for 24 or 48 months at plasma cholesterol concentrations of 300 or 200 mg/dl. , 1981, Experimental and molecular pathology.

[30]  A. Daoud,et al.  Sequential morphologic studies of regression of advanced atherosclerosis. , 1981, Archives of pathology & laboratory medicine.

[31]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[32]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[33]  A. Coats.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002 .

[34]  J. Witztum,et al.  The Oxidative Modification Hypothesis of Atherogenesis , 2000 .

[35]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[36]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[37]  G. A. Rose.  The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. , 1962, Bulletin of the World Health Organization.